IL-17A Blockade Treatment Success in Erythrodermic Pityriasis Rubra Pilaris

Main Article Content

Wylie Masterson
Daniel Morse
Omar Pacha


pityriasis rubra pilaris, secukinumab, IL-17, treatment, prp



Pityriasis rubra pilaris is an inflammatory skin disease with no known etiology or treatment algorithm. PRP patients have an increase in cytokines IL-17A, IL-17F, and IL-22. There are case reports and series that study treatment with agents that block these cytokines, but more research is needed. Our objective is to add to the literature on treatment of PRP with IL-17A blockers.


A 63-year-old man presented with erythrodermic pityriasis rubra pilaris that was diagnosed after biopsy and laboratory tests ruled out other conditions such as psoriasis and Sezary syndrome. He was successfully treated with IL-17 blockade.


Our case demonstrates the successful use of IL-17A blockade for PRP, which suggests that it could be an effective future treatment.


1. Wain T, Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep.2018

2. Brembilla, Nicolo Costantino, Luisa Senra, and Wolf-Henning Boehncke. “The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.” Frontiers in immunology 9 (2018): 1682–1682. Web.

3. SONNEX, T. S et al. “The Nails in Adult Type 1 Pityriasis Rubra Pilaris: a Comparison with Sézary Syndrome and Psoriasis.” Journal of the American Academy of Dermatology 15.5 (1986): 956–960. Print.

4. Brown F, Badri T. Pityriasis Rubra Pilaris. [Updated 2020 Jun 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.

5. Feldmeyer, Laurence et al. “Interleukin 23–Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.” JAMA dermatology (Chicago, Ill.) 153.4 (2017): 304–308. Web.

6. Liu, Taoming et al. “The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside.” Frontiers in immunology 11 (2020): 594735–594735. Web.

7. Wasilewska A, Winiarska M, Olszewska M, Rudnicka L. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33(4):247- 252. doi:10.5114/ada.2016.61599

8. Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab. JAMA Dermatol. 2016;152(11):1278–1279. doi:10.1001/jamadermatol.2016.3885

9. Schuster, Daniel et al. “Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab.” JAMA dermatology (Chicago, Ill.) 152.11 (2016): 1278–1279. Web.

10. Wu, Kevin K, and Harry Dao. “Off-Label Dermatologic Uses of IL-17 Inhibitors.” The Journal of dermatological treatment ahead-of-print.ahead-of-print 1–7. Web.

11. Fala L. Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis. Am Health Drug Benefits. 2016;9(Spec Feature):60-63.

Similar Articles

You may also start an advanced similarity search for this article.